Search alternatives:
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
-
2601
-
2602
-
2603
-
2604
-
2605
-
2606
-
2607
-
2608
-
2609
-
2610
-
2611
-
2612
-
2613
-
2614
-
2615
-
2616
-
2617
-
2618
-
2619
-
2620
Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines.
Published 2013“…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”